RBM38 and non-small cell lung carcinoma: For example, RBM38 was considered to take part in the formation of T-cell lymphoma by regulating mutants p53 and PTEN, but in non-small cell lung cancer (NSCLC), renal carcinoma (RCC), and hepatocellular carcinoma (HCC), RBM38 suppressed the progression of carcinoma (Ding et al., 2014; Huang et al., 2017; Yang et al., 2018; Zhang et al., 2018).